ALLO vs. FATE, BLUE, RLAY, CGON, IOVA, BEAM, IMCR, NVAX, RXRX, and NMRA
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Fate Therapeutics (FATE), bluebird bio (BLUE), Relay Therapeutics (RLAY), CG Oncology (CGON), Iovance Biotherapeutics (IOVA), Beam Therapeutics (BEAM), Immunocore (IMCR), Novavax (NVAX), Recursion Pharmaceuticals (RXRX), and Neumora Therapeutics (NMRA). These companies are all part of the "biological products, except diagnostic" industry.
Fate Therapeutics (NASDAQ:FATE) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
Fate Therapeutics received 209 more outperform votes than Allogene Therapeutics when rated by MarketBeat users. Likewise, 68.67% of users gave Fate Therapeutics an outperform vote while only 64.83% of users gave Allogene Therapeutics an outperform vote.
Fate Therapeutics has higher revenue and earnings than Allogene Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fate Therapeutics presently has a consensus price target of $6.75, indicating a potential upside of 24.08%. Allogene Therapeutics has a consensus price target of $9.95, indicating a potential upside of 231.67%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Fate Therapeutics.
In the previous week, Fate Therapeutics had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for Fate Therapeutics and 3 mentions for Allogene Therapeutics. Fate Therapeutics' average media sentiment score of 1.21 beat Allogene Therapeutics' score of 0.27 indicating that Allogene Therapeutics is being referred to more favorably in the news media.
97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 5.0% of Fate Therapeutics shares are held by company insiders. Comparatively, 24.3% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Fate Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.
Fate Therapeutics has a net margin of -2,933.79% compared to Fate Therapeutics' net margin of -223,139.98%. Allogene Therapeutics' return on equity of -46.49% beat Fate Therapeutics' return on equity.
Summary
Fate Therapeutics beats Allogene Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
